Japan’s Pharmas Need R&D Reform: Tokyo Conference
This article was originally published in PharmAsia News
Executive Summary
TOKYO - The pharmaceutical market is rapidly increasing in complexity and pharmaceutical companies need to strengthen their 'mekiki ryoku' - translated 'eye for good judgment' in Japanese - said Ryoichi Inoue of Pharma Marketing Consultant, who is a former marketing executive at Roche in Japan
You may also be interested in...
Takeda, Others Look To Overseas Growth To Offset Sluggish Japan Market
Takeda Pharmaceutical and fellow Japanese drug makers share a need to look abroad for ways to increase business in a shrinking domestic market. That need was behind Takeda's largest-ever acquisition bid by a Japanese drug maker for a foreign firm, the $8.8 billion offer for the U.S. biotech Millennium Pharmaceuticals. Takeda has a weak business structure in the U.S. and Europe when compared with foreign competitors and needed an acquisition. The domestic pharmaceutical market is considered sluggish despite 4.6 percent growth last year. (Click here for more - a subscription may be required
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).